Mazindol



Mazindol
Systematic (IUPAC) name
 ?
Identifiers
CAS number 22232-71-9
ATC code A08AA05
PubChem 4020
DrugBank APRD01085
Chemical data
O 
Mol. mass 284.74 g/mol
Pharmacokinetic data
Bioavailability 93%
Metabolism Hepatic
Half life 10-13 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

?

Legal status

Schedule IV(US) Schedule IV (International)

Routes Oral

Mazindol is a central nervous system tricyclic antidepressants).

Indications

Mazindol is used in short-term (i.e., a few weeks) treatment of exogenous obesity, in combination with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2), or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, hyperlipidemia.

Pharmacology

Mazindol is a amphetamine. It stimulates the central nervous system, which increases heart rate and blood pressure, and decreases appetite. Sympathomimetic anoretics (appetite suppressants) are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks of treatment. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

Mechanism of Action

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Like other sympathomimetic appetite suppressants such as norepinephrine.

Overdose

Symptoms of a mazindol overdose include: restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.

See also


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mazindol". A list of authors is available in Wikipedia.